Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Health & Science
Recent news which mentions Health & Science
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Nvidia invests $50 million in biotech company Recursion for AI drug discovery
July 12, 2023
Tags
Health care industry
Alphabet Inc
Moderna Inc
From
CNBC.com News
Whistleblower alleges Medtronic engaged in bribery scheme at veterans hospital
July 12, 2023
Tags
Medtronic PLC
Health Care Supplies
Business News
From
CNBC.com News
Illumina hit with record fine for closing Grail deal without EU regulatory approval
July 12, 2023
Tags
Illumina Inc
Health & Science
Pharmaceuticals
From
CNBC.com News
EU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugs
July 11, 2023
Tags
Weight management
Business News
Europe News
From
CNBC.com News
Few patients continue weight loss drugs like Wegovy after a year — but health costs soar for all
July 11, 2023
Tags
Insurance industry
Health care industry
Diabetes
From
CNBC.com News
White House unveils plan to eliminate threat of fentanyl laced with xylazine
July 11, 2023
Tags
US: News
White House
Business
From
CNBC.com News
Novavax stock spikes 20% after company snags $350 million from Canada for unused Covid shots
July 10, 2023
Tags
US: News
Business
Pfizer Inc
From
CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
July 08, 2023
Tags
Eisai Co Ltd
Policy
Breaking News: Business
From
CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
July 07, 2023
Tags
Business News
Law and Regulation
Social issues
From
CNBC.com News
U.S. officials say risk of locally acquired malaria remains low as nationwide cases jump to seven
July 07, 2023
Tags
Malaria
Health care industry
Health
From
CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
July 06, 2023
Tags
Biogen Inc
Social issues
Business News
From
CNBC.com News
Bill Ackman explains why he embraced RFK Jr.'s skepticism on Covid vaccines
July 05, 2023
Tags
Wall Street
Social Media
Medicine
From
CNBC.com News
Moderna strikes deal to develop mRNA drugs in China
July 05, 2023
Tags
Companies
Biotechnology
Novo Nordisk A/S
From
CNBC.com News
Medicare will allow pharmaceutical companies to publicly discuss drug price negotiations
June 30, 2023
Tags
Politics
Biotechnology
Breaking News: Business
From
CNBC.com News
Nike CEO John Donahoe on how he manages sleep health in a hectic life
June 30, 2023
Tickers
CEOS
Tags
Leadership Insights
Health
Wellness
From
CNBC.com News
People should stop taking Ozempic, Wegovy obesity drugs before surgery, doctors group says
June 30, 2023
Tags
Business News
Weight management
Surgical procedures
From
CNBC.com News
The first fully A.I.-generated drug enters clinical trials in human patients
June 29, 2023
Tags
Science
Artificial intelligence
Health & Science
From
CNBC.com News
Hepatitis C cure is not reaching overwhelming majority of patients due to financial barriers
June 29, 2023
Tags
Gilead Sciences Inc
Politics
Biotechnology
From
CNBC.com News
Ex-Pfizer employee charged with illegal trading based on unreleased Covid pill trial data
June 29, 2023
Tags
Companies
Biotechnology
US: News
From
CNBC.com News
CDC recommends RSV vaccines from Pfizer, GSK for adults 60 and older
June 29, 2023
Tags
GSK plc
Biotechnology
Companies
From
CNBC.com News
Justice Department charges 78 people with $2.5 billion in health-care fraud
June 28, 2023
Tags
Collusion
Corruption
Biotech and Pharmaceuticals
From
CNBC.com News
As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edge
June 28, 2023
Tags
US: News
Biotech and Pharmaceuticals
Business
From
CNBC.com News
Regeneron shares fall after FDA rejects high-dose eye disease treatment
June 27, 2023
Tags
Business
Biotech and Pharmaceuticals
US: News
From
CNBC.com News
More than $200 billion in Covid loans potentially stolen by fraudsters, watchdog says
June 27, 2023
Tags
Breaking News: Business
Policy
Epidemics
From
CNBC.com News
OpenAI-powered app from Microsoft is coming to Epic Systems to help save doctors time
June 27, 2023
Tags
Health & Science
Breaking News: Technology
Health care industry
From
CNBC.com News
Don't budget, says financial psychologist. Here's why he recommends a 'spending plan' instead
June 27, 2023
Tags
Personal Finance
Personal finance
Health & Science
From
CNBC.com News
Walgreens slashes earnings guidance due to lower consumer spending, drop in Covid care demand
June 27, 2023
Tags
Business
Breaking News: Business
Dividends
From
CNBC.com News
Eli Lilly experimental obesity drug helped patients lose up to 24% of their weight, study says
June 26, 2023
Tags
Novo Nordisk A/S
Biotechnology
Companies
From
CNBC.com News
Britain's underfunded National Health Service linked to earlier deaths, study says
June 26, 2023
Tags
Europe Economy
Europe: Top News And Analysis
Breaking News: Economy
From
CNBC.com News
Novo Nordisk says high-dose experimental obesity pill leads to 15% weight loss
June 26, 2023
Tags
Health care industry
Biotech and Pharmaceuticals
Diabetes
From
CNBC.com News
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.